Frost & Sullivan Finds the Entrenched Nature of qPCR Technology Sustains the US Reagents Market
-- Performance, quality and familiarity continue as the key purchasing factors
MOUNTAIN VIEW, California, July 31, 2013 /PRNewswire/ -- Quantitative real-time polymerase chain reaction (qPCR) is a technique that has survived for decades, providing validated, publishable data for researchers and holding a favorable reputation for performance and sensitivity. This established technology, in turn, sustains the U.S. qPCR reagents market. As a result, the country's mature qPCR reagents market fared well through rough economic conditions.
According to the Frost & Sullivan analysis, U.S. qPCR Reagents Market, revenues are expected to grow from $650 million in 2012 to reach $858 million in 2017. The research, part of the Life Sciences (http://www.lifesciences.frost.com) Growth Partnership Service program, details market drivers and restraints, trends that will influence future market dynamics and competitive factors driving technology usage.
For more information on this research, please email Britni Myers, Corporate Communications, at britni.myers@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.
"The expanding range of applications that utilize qPCR boost the qPCR reagents market as the continuous restocking of reagents is necessary for work to go on," said Frost & Sullivan Life Sciences Senior Industry Analyst Christi Bird. "Emerging high growth applications, including pharmacogenomics, and microRNA, non-coding RNA and epigenetics research, will add to the demand for qPCR reagents."
However, the market is restrained by maturity in established applications, high saturation and limited growth of qPCR instruments, as well as budget constraints, particularly in academic and government laboratories. Moreover, with several key qPCR patents expiring over the next five years and beyond, an increase in competition will drive down pricing as well as revenues. The problem is compounded when new vendors compete on price to acquire customers. This has already occurred in the SYBR green segment and is expected to spill over to other segments as important patents expire.
Nevertheless, qPCR will maintain its value due to its accuracy, sensitivity, reproducibility, and entrenched usage in molecular biology laboratories. Product specialization, such as the development of qPCR disease or pathway-based panels, microRNA or epigenetics products, and low-volume capabilities, will help thwart price erosion and support niche workflows.
"High quality suppliers should have little trouble maintaining customers, as performance, quality and comfort are still key purchasing factors for qPCR reagents," noted Bird. "Researchers in the United States are unwilling to sacrifice these features for price alone."
Frost & Sullivan's related Life Sciences research includes: Global Mass Spectrometry Market, Cell Culture Purchasing Trends, and Analysis of the Asia-Pacific Molecular Diagnostics Market. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
Connect with Frost & Sullivan on social media, including Twitter, Facebook, SlideShare and LinkedIn, for the latest news and updates.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion
Subscribe: Newsletter on "the next big thing"
Register: Gain access to visionary innovation
U.S. qPCR Reagents Market
NBE1-52
Contact:
Britni Myers
Corporate Communications – North America
P: +1.210.477.8481
F: +1.210.348.1003
E: britni.myers@frost.com
Twitter: @frost_sullivan
Facebook: Frost & Sullivan
http://www.frost.com
Share this article